Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology-Reference-Cited by-同舟云学术

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

Published:2019-01 Issue:1 Volume:75 Page:88-99
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Nuhn Philipp,De Bono Johann S.,Fizazi Karim,Freedland Stephen J.,Grilli Maurizio,Kantoff Philip W.,Sonpavde Guru,Sternberg Cora N.,Yegnasubramanian Srinivasan,Antonarakis Emmanuel S.

Publisher

Elsevier BV

Subject

Urology

Reference99 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer;Heidenreich;Eur Urol,2014

3. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level;Karantanos;Eur Urol,2015

4. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial;Gravis;Eur Urol,2016

5. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group;Scher;J Clin Oncol,2008

Cited by 345 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. mtPCDI: a machine learning-based prognostic model for prostate cancer recurrence;Frontiers in Genetics;2024-09-04

2. Prostate Cancer: Emerging Modifiable Risk Factors and Therapeutic Strategies in the Management of Advanced Cancer;Life;2024-08-30

3. Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer Patients;European Urology Open Science;2024-08

4. Current Understanding of Androgen Signaling in Prostatitis and its Treatment: A Review;Current Medicinal Chemistry;2024-08

5. Investigating miR-6880-5p in extracellular vesicle from plasma as a prognostic biomarker in endocrine therapy-treated castration-resistant prostate cancer;BMC Cancer;2024-07-29